A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. - Wikidata - awgldk - TriplyDB

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.

http://www.wikidata.org/entity/Q38356952

about

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Catalytic mechanism of human alpha-galactosidase A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes Agalsidase alfa: a review of its use in the management of Fabry disease Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry.Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry Disease Enhanced sialylation and in vivo efficacy of recombinant human α-galactosidase through in vitro glycosylation The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α Enzyme replacement therapy for Fabry disease: some answers but more questions Structure-function relationships in alpha-galactosidase A.Update on role of agalsidase alfa in management of Fabry disease.Carboxyl-terminal truncations alter the activity of the human α-galactosidase A Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys Cellular and tissue distribution of intravenously administered agalsidase alfa.Innate and Adaptive Immune Response in Fabry Disease Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.Diagnosis of lysosomal storage disorders: current techniques and future directions.Analytical detection and characterization of biopharmaceutical glycosylation by MS.Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience Agalsidase benefits renal histology in young patients with Fabry disease.Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice Novel therapeutic targets for the treatment of Fabry disease.Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).Fabry disease-often seen, rarely diagnosed.Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease Fabry disease in children and the effects of enzyme replacement treatment.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.

P2860

Q21004071-5DACB517-30E8-42A0-BEFE-AB62FB563467 Q21202889-A349341E-BEF4-4854-ACF6-169F7A7539E4 Q24650910-3676BE40-2DB6-4CE6-A381-98185E4A4205 Q27658332-CF606AEC-99A5-4A79-8110-E5EA2C002B31 Q27683473-1782E7D2-3B3C-4B17-8637-BFA2EE29DB24 Q28274194-B372FF37-1E11-419A-ACA8-3CE2D77E7FAB Q28477142-BEB11FB3-5ADC-49A0-8721-B546F79FE4D1 Q28727768-6C05E9E0-E3BF-4E81-AE45-831B1BA9B090 Q30458149-D4E0E826-8722-4328-9D12-F039652A64AF Q33252266-FC1353BC-9D97-47E5-907B-4A09A24CC530 Q33586660-EC654E48-CA78-4110-B64F-7ACFC82C7CCA Q33818578-B533F3E2-1B44-442E-A76C-9578CB2180C9 Q33819347-8A414597-3611-45C1-81FE-0CC7AFEDD5E7 Q34049393-E2FCF532-F21B-44D9-83D7-A6928FCAEA22 Q34137441-1008FAFF-9E10-4A3B-80FE-0675DABDE195 Q34304963-6758AB6D-E046-431B-B327-12E80F71ECFF Q34703815-AAEF22B0-A44B-44FF-8FC5-73E61FF13309 Q34731206-C60A9BDF-974D-4E3E-B0BA-DE8305F2319A Q34883178-CB5584E4-7009-4394-803A-0DFA0E0E7D01 Q35125851-C6F67A8D-8B76-41CC-B924-0F3A8F049C0C Q35665871-21EA2587-0AB6-49AA-AA76-B31F95B2C880 Q35719001-8DD35FD5-C211-4692-A5AA-9A7347600AA8 Q35728693-EC7DF025-869C-41CF-87F9-12357B216172 Q35800976-65ECBCB1-C0CF-4FC2-8A4D-1A50EEE5569C Q35842694-DDFD55A0-5EC6-4194-B678-9E367180B448 Q35878288-5ABCE539-AE5E-4220-89F6-CDCF635C350E Q35953047-5CF37BC6-2B36-46C8-A944-5CCA570A3CE8 Q36433306-43E71A29-F90D-4CCC-B448-EA9C5D466120 Q36509288-D32AE746-9B65-4905-9DEE-981870ABA39C Q36582247-4BEBEB1F-1DD8-45C1-97B7-CFD05224F1FB Q36596408-4B49D43D-F3E2-4BBA-9ECE-9535329BF9D3 Q36607211-29FF65CF-8BC7-4F5B-B7B8-A2B039365D00 Q36756784-06378454-403A-4945-8187-EDC87DDEA73B Q36822452-0D5B32B4-DFEC-4DF4-90F9-972A1BCEA647 Q36853823-EF6DDF4A-2630-49C7-9735-7EEE115FE4E3 Q37138255-3CCF920C-34FB-4700-9E30-EF93A2CC8B6C Q37246955-B0A32C3E-0EA1-459E-8889-E27FDE69FEFF Q37329223-07AEB6C1-8B30-4251-9DAC-C357D9F05AB4 Q37350401-1A838018-30D9-40DE-AA1A-251A030C1459 Q37494846-79E7B27F-8D92-4C68-A29F-95A27B6CF761

P2860

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.

http://www.wikidata.org/entity/Q38356952

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

A biochemical and pharmacologi ...... torage disorder Fabry disease.

@en

type

label

A biochemical and pharmacologi ...... torage disorder Fabry disease.

@en

prefLabel

A biochemical and pharmacologi ...... torage disorder Fabry disease.

@en

P1433

Q38356952-F77D1FFD-768C-4F37-B7BA-28F1EB797BB1

P1476

Q38356952-8D7642ED-4C5D-4773-86B1-017CB7EAD14A

P2093

Q38356952-19A9A823-7BC2-4883-A665-F42E884BB019

Q38356952-21C9DA02-BD6D-4694-A221-317B2B5482F4

Q38356952-3A12AE57-C373-472D-B15C-B09114B46265

Q38356952-4E5B68A0-1539-4AD9-BA53-68EE7A1564AA

Q38356952-79265CBE-DA1E-44D5-B6CF-AF5F794BDF3F

Q38356952-AB193900-0B24-4353-8DB8-1D987695D8B2

Q38356952-AB58CC47-B3E2-4AB9-98F9-5CD4CB68778A

Q38356952-C0078201-964A-4411-A131-9D68C8AC91D8

Q38356952-D6EA59B8-1F6A-48F3-8E20-6253A7668F17

Q38356952-F297D655-1D2D-4456-9EA2-8DED2056901D

P304

Q38356952-40213B90-BD2E-4F09-B3E8-6CDE8373FA0C

P31

Q38356952-C30F0132-55D2-4856-9833-A1288863CB13

P356

Q38356952-12E70C3E-86C0-42F6-BF25-5707AF450A58

P433

Q38356952-8EA74B3F-4120-4D87-A618-2872D75DC6F0

P478

Q38356952-4C285D29-130F-4B36-8103-94166AB7B4F7

P577

Q38356952-2CF63236-7D1C-4C7D-86EA-1AFA536DCC5D

P5875

Q38356952-6BBE2772-13F3-4208-B945-E8F441456C51

P698

Q38356952-51957B18-D894-4871-A5D6-D108D6B3516C

P356

P1433

P1476

A biochemical and pharmacologi ...... torage disorder Fabry disease.

@en

P2093

Debra Barngrover

http://www.w3.org/2001/XMLSchema#string

Huawei Qiu

http://www.w3.org/2001/XMLSchema#string

Jennifer Baker-Malcolm

http://www.w3.org/2001/XMLSchema#string

John M McPherson

http://www.w3.org/2001/XMLSchema#string

Karen Lee

http://www.w3.org/2001/XMLSchema#string

Kate Zhang

http://www.w3.org/2001/XMLSchema#string

Keirsten Seiger

http://www.w3.org/2001/XMLSchema#string

Laura Andrews

http://www.w3.org/2001/XMLSchema#string

Laura Geagan

http://www.w3.org/2001/XMLSchema#string

Lorraine Copertino

http://www.w3.org/2001/XMLSchema#string

P304

305-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/GLYCOB/CWG034

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10866219

http://www.w3.org/2001/XMLSchema#string

P698

12626384

http://www.w3.org/2001/XMLSchema#string